Full Press Release Details
to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020
Israel, May 11, 2020 -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that
it will release financial results for the first quarter ended March 31, 2020, prior to the open of the U.S. financial markets
on Monday, May 18, 2020.
management will host an investment community conference call on Monday, May 18, at 8:30am Eastern Time to discuss these results
and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792
(from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification
number: 13699990. The call will also be webcast live on the Internet on the Company's website at www.kamada.com.
call will also be archived for 90 days on the Company's website at www.kamada.com.
Ltd. ("the Company") is a commercial stage plasma-derived biopharmaceutical company focused on orphan indications,
with an existing marketed product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology
and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified,
liquid form, as well as other plasma-derived immune globulins. The Company's flagship product is GLASSIA , the first
liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S.
through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other countries through local distributors.
The Company's second leading product is KamRab , a rabies immune globulin (Human) for post-exposure prophylaxis against
rabies infection. KamRab is FDA approved and is being marketed in the U.S. under the brand name KEDRAB through a strategic
partnership with Kedrion S.p.A. In addition to Glassia and KEDRAB, the Company has a product line of four other plasma-derived
pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries,
including Israel, Russia, Brazil, India and other countries in Latin America and Asia. The Company has late-stage products in
development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition, the Company's intravenous
AAT is in development for other indications, such as GvHD and prevention of lung transplant rejection. The Company leverages its
expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in
Israel that are manufactured by third parties. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's
lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.